The editorial selected posed the question of whether increases in PTH levels and hypocalcemia during bisphosphonate treatment in patients with metastatic breast cancer could be predisposing factors to osteonecrosis of the jaw. The gene discussed is PTH; the disease is Hypocalcemia.